Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CVR Medical Corp CRRVF

CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool which complements other stroke screening technology, such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), and computed tomography angiography (CTA). The CSS is 100% non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers. The CVR device uses only sound wave analysis to detect the presence of arterial stenosis.


GREY:CRRVF - Post by User

Comment by ICT1111on Apr 01, 2021 11:47pm
183 Views
Post# 32931145

RE:RE:Tumbleweed

RE:RE:TumbleweedYou are spot on Nastro. Bakema has been running around for nearly two years now trying to find someone to fund this on his terms. In fact since the re-structuring group told the board in May 2019 that their structure and MO was tainted (TSX CTO and letter from FDA re short comings in the clinical trials) and that the board should not expect there to be any further fund raising until both were sorted out........ nearly two years later, no further forward, in fact, in reverse. 
<< Previous
Bullboard Posts
Next >>